At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 34 enrolled
Drug / intervention
Canagliflozin +1 moredrug
Likely dose
Canagliflozin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of Canagliflozin on Gene Expression and Function of CD34+ Endothelial Progenitor Cells and Renal Function in Patients With Type 2 Diabetes
In Brief
A Phase 4 clinical trial evaluating Canagliflozin and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The investigators hypothesize that Cana may be able to improve number and function of CD34+ endothelial progenitor cells. The investigators also propose that this expected cardiovascular benefit is independent of HbA1C reduction. Subjects will begin taking 100 mg of Cana or placebo after initial 4 weeks. Subjects will be withdrawn from the study if the medication or placebo is not tolerated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
CollaboratorsJanssen Scientific Affairs, LLC
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedNov 2016
Primary CompletionJan 2020
Study CompletionSep 2020
TodayJul 2026
First PostedNov 16, 2016
Enrollment StartNov 1, 2016
Primary CompletionJan 1, 2020
Study CompletionSep 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 9.6 years ago
Interventions
Canagliflozindrug
100 mg
Placebodrug
1 tablet daily for 16 weeks